Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06744816 · ClinicalTrials.gov registry record · Early Phase 1
Exploring the Benefit of Topical Capsaicin in Treating Pain From Chemo-induced Peripheral Neuropathy: a Longitudinal Single Center Pilot Study
A Early Phase 1 study of Peripheral Neuropathy Due to Chemotherapy, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06744816 is a Early Phase 1 study of Peripheral Neuropathy Due to Chemotherapy that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 20 participants, below the 58-participant average among 6 other Peripheral Neuropathy Due to Chemotherapy trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06744816, a Early Phase 1 study of Peripheral Neuropathy Due to Chemotherapy, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn if topical capsaicin can help relieve pain from CIPN and improve gait (the pattern of walking) in patients.
Conditions Studied
Interventions
- DRUG Qutenza Patch
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-12-11 |
| Est. Completion | 2027-11-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06744816
The ClinicalTrials.gov registry entry for NCT06744816 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 58-participant average among 6 other Peripheral Neuropathy Due to Chemotherapy trials with a reported enrollment target (66% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Peripheral Neuropathy Due to Chemotherapy appearing as the primary indexed condition, and to 1 intervention - of which Qutenza Patch is the first listed.
NCT06744816 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06744816 about?
NCT06744816 is a clinical study titled "Exploring the Benefit of Topical Capsaicin in Treating Pain From Chemo-induced Peripheral Neuropathy: a Longitudinal Single Center Pilot Study". To learn if topical capsaicin can help relieve pain from CIPN and improve gait (the pattern of walking) in patients.
What is the current status of trial NCT06744816?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2025-12-11. Estimated completion is 2027-11-30.
What conditions does trial NCT06744816 study?
This clinical trial studies the following conditions: Peripheral Neuropathy Due to Chemotherapy.
What interventions are being tested in trial NCT06744816?
The interventions under investigation include: Qutenza Patch (DRUG).
Who is sponsoring clinical trial NCT06744816?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06744816 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Neuropathy Due to Chemotherapy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy
RECRUITING · Early Phase 1
-
Balance4Mobility: Effects of Walkasins Use in Individuals With Peripheral Neuropathy and Balance Problems
RECRUITING · NA
-
Feasibility Testing of a Tai Chi Program for Chemotherapy-Induced Peripheral Neuropathy Treatment (TCT)
RECRUITING · NA
-
Patient-identified Values as Outcome Targets (PIVOT) Feasibility Pilot Trial
RECRUITING · NA
-
Fall Risk and Quality of Life: in Individuals With Cancer Treatment Related Peripheral Neuropathy.
RECRUITING
-
Closed Loop Spinal Cord Stimulation for Chemotherapy Induced Peripheral Neuropathy, a Pilot Study.
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.